|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,239.50 INR | +0.18% |
|
-1.90% | +10.04% |
| 07-07 | India finds Adani's Mumbai airport shops sold nicotine pouches in breach of law | RE |
| 07-06 | Glenmark Pharmaceuticals Launches Olanzapine for Injection | MT |
Company Valuation: Glenmark Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 131,124 | 124,718 | 131,124 | 270,463 | 434,866 | 631,989 | - | - |
| Change | - | -4.88% | 5.14% | 106.27% | 60.79% | 45.33% | - | - |
| Enterprise Value (EV) 1 | 162,310 | 150,223 | 162,699 | 263,786 | 442,540 | 595,740 | 594,867 | 582,626 |
| Change | - | -7.45% | 8.3% | 62.13% | 67.76% | 34.62% | 0.37% | -2.06% |
| P/E | 13.5x | 13.2x | 44.1x | -18x | 41.5x | 44.2x | 26.9x | 22.2x |
| PBR | 1.86x | 1.37x | 1.38x | 3.45x | 4.91x | 5.72x | 5x | 4.15x |
| PEG | - | -4.63x | -0.6x | 0x | -0x | 1.5x | 1x | 1x |
| Capitalization / Revenue | 1.2x | 1.01x | 1.01x | 2.29x | 3.26x | 3.54x | 3.79x | 3.41x |
| EV / Revenue | 1.48x | 1.22x | 1.25x | 2.23x | 3.32x | 3.51x | 3.57x | 3.14x |
| EV / EBITDA | 7.79x | 6.47x | 7.14x | 22.1x | 18.8x | 13x | 16.5x | 13.5x |
| EV / EBIT | 9.89x | 8.19x | 9.76x | 43x | 23.7x | 14.9x | 19.6x | 16x |
| EV / FCF | 45.5x | 47.2x | 923x | -22.7x | -28.1x | 28.5x | 36.3x | 30.9x |
| FCF Yield | 2.2% | 2.12% | 0.11% | -4.41% | -3.56% | 3.5% | 2.76% | 3.24% |
| Dividend per Share 2 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 2.5 | 5.359 | 6.016 |
| Rate of return | 0.54% | 0.57% | 0.54% | 0.26% | 0.16% | 0.12% | 0.24% | 0.27% |
| EPS 2 | 34.38 | 33.4 | 10.53 | -53.22 | 37.11 | 48.24 | 83.33 | 101 |
| Distribution rate | 7.27% | 7.49% | 23.7% | -4.7% | 6.74% | 5.18% | 6.43% | 5.95% |
| Net sales 1 | 109,439 | 123,409 | 129,901 | 118,131 | 133,217 | 169,825 | 166,719 | 185,361 |
| EBITDA 1 | 20,844 | 23,203 | 22,784 | 11,953 | 23,514 | 45,724 | 36,162 | 43,035 |
| EBIT 1 | 16,408 | 18,336 | 16,671 | 6,134 | 18,654 | 39,989 | 30,343 | 36,353 |
| Net income 1 | 9,701 | 9,936 | 2,972 | -15,017 | 10,471 | 13,619 | 23,282 | 28,228 |
| Net Debt 1 | 31,187 | 25,505 | 31,575 | -6,677 | 7,674 | -5,827 | -37,122 | -49,362 |
| Reference price 2 | 464.70 | 442.00 | 464.70 | 958.45 | 1,541.05 | 2,239.50 | 2,239.50 | 2,239.50 |
| Nbr of stocks (in thousands) | 282,168 | 282,168 | 282,168 | 282,188 | 282,188 | 282,201 | - | - |
| Announcement Date | 5/28/21 | 5/27/22 | 5/19/23 | 5/24/24 | 5/23/25 | 5/29/26 | - | - |
1INR in Million2INR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.93x | 3.86x | 16.44x | 0.24% | 6.55B | |
| 35.28x | 6.67x | 23.05x | 0.82% | 48.15B | |
| 18.13x | 2.05x | 9.64x | 1.32% | 35.59B | |
| 27.27x | 3.37x | 17.25x | 0.86% | 11.9B | |
| 27.11x | 3.99x | 16.27x | 0.58% | 11.85B | |
| 19.66x | 3.44x | 12.36x | 3.39% | 9.31B | |
| 16.06x | 2.07x | 6.96x | 3.23% | 7.02B | |
| 8.37x | 1.97x | 5.15x | 5.18% | 6.91B | |
| Average | 23.23x | 3.43x | 13.39x | 1.95% | 17.16B | |
| Weighted average by Cap. | 25.98x | 4.13x | 15.72x | 1.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLENMARK Stock
- Valuation Glenmark Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
